Cannabis (Cannabis sativa)
Influence of cannabidiol on secobarbital effects and plasma kinetics
CSV
JSON
To investigate the possible metabolic interaction between cannabidiol (CBD) and secobarbital, 6 male volunteers received 150 mg/70 kg sodium secobarbital orally immediately after smoking a marihuana cigarette prepared to deliver 0, 150, or 500 µg/kg CBD. The study was performed in a double-blind manner with each of the three treatments being assigned to every subject. Clinical effects and plasma secobarbital concentrations were recorded at periodic intervals. CBD did not alter the summary parameters which describe the secobarbital plasma concentration time curve. Secobarbital half-life, peak concentration, time of peak concentration, and area under the curve were unchanged by the coadministration of CBD. Clinical effects of secobarbital were also unaltered by CBD pretreatment. Thus at the doses administered, CBD does not appear to inhibit secobarbital metabolism in man.
1 . Secobarbital Plasma Concentrations Following Sodium Secobarbital Ingestion and 150 µg/kg CBD Pretreatment (id=NPDI-noOe3w)
In Vivo Interaction Study
No Effect (based on bioequivalence limits) was detected.
Figure 1
Results
Values estimated from Figure 1 and converted from µg/mL. Original estimated value: 2.5 µg/mL.
| Sample | Compound measured | Value | Measurement | Study sequence | Additional information | N replicates |
|---|
Experimental Conditions
Double-blind
Placebo-controlled
Single dosing
Healthy volunteers
Males
6
"No subjects used drugs or medication habitually, but all had previously smoked marijuana. Subjects were instructed to fast at least four hours prior to the experimental session and to eat a light breakfast consisting of dry toast and juice. [...] All sessions were separated by at least one week."
0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 min, 24, 48, and 72 h
Drug or Natural Product Administration
Oral
Capsule
150 mg/70 kg
Once
Inhalation
Cigarette
150 µg/kg
Once
Not specified
2 . Secobarbital Plasma Concentrations Following Sodium Secobarbital Ingestion and 500 µg/kg CBD Pretreatment (id=NPDI-SCT2WA)
In Vivo Interaction Study
No Effect (based on bioequivalence limits) was detected.
Figure 1
Results
Values estimated from Figure 1. Original value was converted to ng/mL: Cmax (µg/mL): 2.75
| Sample | Compound measured | Value | Measurement | Study sequence | Additional information | N replicates |
|---|
Experimental Conditions
Double-blind
Placebo-controlled
Single dosing
Healthy volunteers
Males
6
"No subjects used drugs or medication habitually, but all had previously smoked marijuana. Subjects were instructed to fast at least four hours prior to the experimental session and to eat a light breakfast consisting of dry toast and juice. [...] All sessions were separated by at least one week."
0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 min, 24, 48, and 72 h
Drug or Natural Product Administration
Oral
Capsule
150 mg/70 kg
Once
Inhalation
Cigarette
500 µg/kg
Once
Not specified
3 . Plasma Concentrations of Secobarbital After Placebo Pretreatment and Oral Administration of Secobarbital (id=NPDI-tUG7XA)
In Vivo Interaction Study
No Effect (based on bioequivalence limits) was detected.
Table 1.
Results
Values converted from µg/mL.
Original value: Cmax (µg/mL): 2.59 ± 0.94
Table 1.
| Sample | Compound measured | Value | Measurement | Study sequence | Additional information | N replicates |
|---|
Experimental Conditions
Double-blind
Placebo-controlled
Single dosing
Healthy volunteers
Males
6
"No subjects used drugs or medication habitually, but all had previously smoked marijuana. Subjects were instructed to fast at least four hours prior to the experimental session and to eat a light breakfast consisting of dry toast and juice. [...] All sessions were separated by at least one week."
0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 min, 24, 48, and 72 h
Drug or Natural Product Administration
Oral
Capsule
150 mg/70 kg
Once
Inhalation
Cigarette
0 mg
Once
Not specified